header

Articles

Vol. 1 No. 1 (2025): Journal of Advanced Nursing and Health Systems Innovation (JANHSI)

STUDI KAJIAN IN VITRO SEL MCF-7: POTENSI BIOAKTIVITAS MULTITARGET SULFORAFAN SEBAGAI FITOKIMIA TERHADAP KARSINOGENESIS KANKER PAYUDARA SUBTIPE LUMINAL A

Submitted
January 21, 2026
Published
21.02.2026

Abstract

Latar Belakang – Kanker payudara menjadi penyumbang utama angka mortalitas kanker pada wanita. Kanker payudara subtipe luminal A merupakan subtipe yang paling sering ditemukan dibanding subtipe lainnya. Kanker payudara subtipe luminal A berkaitan erat dengan sel lini MCF-7 yang merupakan sel dengan reseptor berupa estrogen, progesteron, dan glukokortikoid. Dalam literature review ini, akan dipaparkan mengenai regulasi jalur persinyalan SFN sebagai penghambat proliferasi sel MCF-7.

Tujuan – Studi ini bertujuan untuk mengkaji dan mensintesis bukti ilmiah mengenai peran sulforafan dalam meregulasi jalur persinyalan molekuler sebagai penghambat proliferasi sel kanker payudara subtipe luminal A, khususnya pada sel lini MCF-7, serta mengevaluasi potensinya sebagai kandidat terapi adjuvan kanker payudara.

Metode– Penulisan dilakukan dengan metode studi literatur menggunakan referensi yang memiliki korelasi dengan topik bahasan ini.

Hasil – Senyawa sulforafan dapat menurunkan tingkat proliferasi sel MCF-7 melalui 3 jalur utama, yaitu cell cycle arrest, cell death (apoptosis), dan stres oksidatif.

Kesimpulan – Tinjauan literatur ini menyajikan sintesis komprehensif mengenai regulasi jalur persinyalan sulforafan sebagai penghambat proliferasi sel MCF-7 pada kanker payudara subtipe luminal A. Temuan ini menegaskan potensi sulforafan sebagai kandidat terapi adjuvan pada kanker payudara subtipe luminal A serta menyoroti pentingnya penelitian lanjutan, khususnya studi translasi dan uji in vivo pada manusia melalui pendekatan kombinasi terapi dan enkapsulasi untuk meningkatkan bioavailabilitas dan efektivitas klinis.

References

  1. Alfarsi, L., Johnston, S., Liu, D., Rakha, E., & Green, A. R. (2018). Current issues with luminal subtype classification in terms of prediction of benefit from endocrine therapy in early breast cancer. Histopathology, 73(4), 545–558. https://doi.org/10.1111/his.13523
  2. Cao, S., Wang, L., Zhang, Z., Chen, F., Wu, Q., & Li, L. (2018). Sulforaphane‐induced metabolomic responses with epigenetic changes in estrogen receptor positive breast cancer cells. FEBS Open Bio, 8(12), 2022–2034. https://doi.org/10.1002/2211-5463.12543
  3. Christinat, A., Lascio, S. Di, & Pagani, O. (2013). Hormonal therapies in young breast cancer patients: When, what and for how long? Journal of Thoracic Disease, 5(SUPPL.1). https://doi.org/10.3978/j.issn.2072-1439.2013.05.25
  4. Comşa, Ş., Cîmpean, A. M., & Raica, M. (2015). The story of MCF-7 breast cancer cell line: 40 Years of experience in research. Anticancer Research, 35(6), 3147–3154.
  5. Danafar, H., Sharafi, A., Kheiri Manjili, H., & Andalib, S. (2017). Sulforaphane delivery using mPEG–PCL co-polymer nanoparticles to breast cancer cells. Pharmaceutical Development and Technology, 22(5), 642–651. https://doi.org/10.3109/10837450.2016.1146296
  6. Feng, Y., Spezia, M., Huang, S., Yuan, C., Zeng, Z., Zhang, L., Ji, X., Liu, W., Huang, B., Luo, W., Liu, B., Lei, Y., Du, S., Vuppalapati, A., Luu, H. H., Haydon, R. C., He, T.-C., & Ren, G. (2018). Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes & Diseases, 5(2), 77–106. https://doi.org/10.1016/j.gendis.2018.05.001
  7. Ghareghomi, S., Habibi-Rezaei, M., Arese, M., Saso, L., & Moosavi-Movahedi, A. A. (2022). Nrf2 Modulation in Breast Cancer. Biomedicines, 10(10), 2668. https://doi.org/10.3390/biomedicines10102668
  8. Ghareghomi, S., Rahban, M., Moosavi-Movahedi, Z., Habibi-Rezaei, M., Saso, L., & Moosavi-Movahedi, A. A. (2021). The Potential Role of Curcumin in Modulating the Master Antioxidant Pathway in Diabetic Hypoxia-Induced Complications. Molecules, 26(24), 7658. https://doi.org/10.3390/molecules26247658
  9. Hussain, A., Mohsin, J., Prabhu, S. A., Begum, S., Nusri, Q. E.-A., Harish, G., Javed, E., Khan, M. A., & Sharma, C. (2013). Sulforaphane Inhibits Growth of Human Breast Cancer Cells and Augments the Therapeutic Index of the Chemotherapeutic Drug, Gemcitabine. Asian Pacific Journal of Cancer Prevention, 14(10), 5855–5860. https://doi.org/10.7314/APJCP.2013.14.10.5855
  10. Inic, Z., Zegarac, M., Inic, M., Markovic, I., Kozomara, Z., Djurisic, I., Inic, I., Pupic, G., & Jancic, S. (2014). Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information. Clinical Medicine Insights: Oncology, 8, CMO.S18006. https://doi.org/10.4137/CMO.S18006
  11. Jardim, F. R., de Almeida, F. J. S., Luckachaki, M. D., & de Oliveira, M. R. (2020). Effects of sulforaphane on brain mitochondria: mechanistic view and future directions. Journal of Zhejiang University-SCIENCE B, 21(4), 263–279. https://doi.org/10.1631/jzus.B1900614
  12. Johnson, K. S., Conant, E. F., & Soo, M. S. (2021). Molecular Subtypes of Breast Cancer: A Review for Breast Radiologists. Journal of Breast Imaging, 3(1), 12–24. https://doi.org/10.1093/jbi/wbaa110
  13. Kaiser, A. E., Baniasadi, M., Giansiracusa, D., Giansiracusa, M., Garcia, M., Fryda, Z., Wong, T. L., & Bishayee, A. (2021). Sulforaphane: A Broccoli Bioactive Phytocompound with Cancer Preventive Potential. Cancers, 13(19), 4796. https://doi.org/10.3390/cancers13194796
  14. Kamal, M. M., Akter, S., Lin, C.-N., & Nazzal, S. (2020). Sulforaphane as an anticancer molecule: mechanisms of action, synergistic effects, enhancement of drug safety, and delivery systems. Archives of Pharmacal Research, 43(4), 371–384. https://doi.org/10.1007/s12272-020-01225-2
  15. Koren, S., Reavie, L., Couto, J. P., De Silva, D., Stadler, M. B., Roloff, T., Britschgi, A., Eichlisberger, T., Kohler, H., Aina, O., Cardiff, R. D., & Bentires-Alj, M. (2015). PIK3CAH1047R induces multipotency and multi-lineage mammary tumours. Nature, 525(7567), 114–118. https://doi.org/10.1038/nature14669
  16. Kuchenbaecker, K. B., Hopper, J. L., Barnes, D. R., Phillips, K.-A., Mooij, T. M., Roos-Blom, M.-J., Jervis, S., van Leeuwen, F. E., Milne, R. L., Andrieu, N., Goldgar, D. E., Terry, M. B., Rookus, M. A., Easton, D. F., Antoniou, A. C., McGuffog, L., Evans, D. G., Barrowdale, D., Frost, D., … Olsson, H. (2017). Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA, 317(23), 2402. https://doi.org/10.1001/jama.2017.7112
  17. Kuran, D., Pogorzelska, A., & Wiktorska, K. (2020). Breast Cancer Prevention-Is there a Future for Sulforaphane and Its Analogs? Nutrients, 12(6), 1559. https://doi.org/10.3390/nu12061559
  18. Lawrenti, H. (2022). Penghambat CDK4/6 untuk Terapi Kanker Payudara. Cermin Dunia Kedokteran, 49(5), 284. https://doi.org/10.55175/cdk.v49i5.1854
  19. Lee, A. V., Oesterreich, S., & Davidson, N. E. (2015). MCF-7 Cells--Changing the Course of Breast Cancer Research and Care for 45 Years. JNCI Journal of the National Cancer Institute, 107(7), djv073–djv073. https://doi.org/10.1093/jnci/djv073
  20. Lewinska, A., Adamczyk-Grochala, J., Deregowska, A., & Wnuk, M. (2017). Sulforaphane-Induced Cell Cycle Arrest and Senescence are accompanied by DNA Hypomethylation and Changes in microRNA Profile in Breast Cancer Cells. Theranostics, 7(14), 3461–3477. https://doi.org/10.7150/thno.20657
  21. Lubecka-Pietruszewska, K., Kaufman-Szymczyk, A., Stefanska, B., Cebula-Obrzut, B., Smolewski, P., & Fabianowska-Majewska, K. (2015). Sulforaphane Alone and in Combination with Clofarabine Epigenetically Regulates the Expression of DNA Methylation-Silenced Tumour Suppressor Genes in Human Breast Cancer Cells. Lifestyle Genomics, 8(2), 91–101. https://doi.org/10.1159/000439111
  22. Mahn, A., & Castillo, A. (2021). Potential of Sulforaphane as a Natural Immune System Enhancer: A Review. Molecules, 26(3), 752. https://doi.org/10.3390/molecules26030752
  23. Matro, J. M., Li, T., Cristofanilli, M., Hughes, M. E., Ottesen, R. A., Weeks, J. C., & Wong, Y.-N. (2015). Inflammatory Breast Cancer Management in the National Comprehensive Cancer Network: The Disease, Recurrence Pattern, and Outcome. Clinical Breast Cancer, 15(1), 1–7. https://doi.org/10.1016/j.clbc.2014.05.005
  24. Mori, N., Shimazu, T., Sasazuki, S., Nozue, M., Mutoh, M., Sawada, N., Iwasaki, M., Yamaji, T., Inoue, M., Takachi, R., Sunami, A., Ishihara, J., Sobue, T., & Tsugane, S. (2017). Cruciferous Vegetable Intake Is Inversely Associated with Lung Cancer Risk among Current Nonsmoking Men in the Japan Public Health Center (JPHC) Study. The Journal of Nutrition, 147(5), 841–849. https://doi.org/10.3945/jn.117.247494
  25. Mukohara, T. (2015). PI3K mutations in breast cancer: prognostic and therapeutic implications. Breast Cancer: Targets and Therapy, 111. https://doi.org/10.2147/BCTT.S60696
  26. Orrantia-Borunda, E., Anchondo-Nuñez, P., Acuña-Aguilar, L. E., Gómez-Valles, F. O., & Ramírez-Valdespino, C. A. (2022). Breast Cancer.
  27. Pal, S., & Badireenath Konkimalla, V. (2016). Hormetic Potential of Sulforaphane (SFN) in Switching Cells’ Fate Towards Survival or Death. Mini-Reviews in Medicinal Chemistry, 16(12), 980–995. https://doi.org/10.2174/1389557516666151120115027
  28. Paul, B., Li, Y., & Tollefsbol, T. (2018). The Effects of Combinatorial Genistein and Sulforaphane in Breast Tumor Inhibition: Role in Epigenetic Regulation. International Journal of Molecular Sciences, 19(6), 1754. https://doi.org/10.3390/ijms19061754
  29. Pawlik, A., Słomińska-Wojewódzka, M., & Herman-Antosiewicz, A. (2016). Sensitization of estrogen receptor-positive breast cancer cell lines to 4-hydroxytamoxifen by isothiocyanates present in cruciferous plants. European Journal of Nutrition, 55(3), 1165–1180. https://doi.org/10.1007/s00394-015-0930-1
  30. Pham, T. T., Angus, S. P., & Johnson, G. L. (2013). MAP3K1: Genomic Alterations in Cancer and Function in Promoting Cell Survival or Apoptosis. Genes & Cancer, 4(11–12), 419–426. https://doi.org/10.1177/1947601913513950
  31. Prat, A., Pineda, E., Adamo, B., Galván, P., Fernández, A., Gaba, L., Díez, M., Viladot, M., Arance, A., & Muñoz, M. (2015). Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast, 24, S26–S35. https://doi.org/10.1016/j.breast.2015.07.008
  32. Rahban, M., Habibi-Rezaei, M., Mazaheri, M., Saso, L., & Moosavi-Movahedi, A. A. (2020). Anti-Viral Potential and Modulation of Nrf2 by Curcumin: Pharmacological Implications. Antioxidants, 9(12), 1228. https://doi.org/10.3390/antiox9121228
  33. Rezaei, A., Fathi, M., & Jafari, S. M. (2019). Nanoencapsulation of hydrophobic and low-soluble food bioactive compounds within different nanocarriers. Food Hydrocolloids, 88, 146–162. https://doi.org/10.1016/j.foodhyd.2018.10.003
  34. Royston, K. J., Paul, B., Nozell, S., Rajbhandari, R., & Tollefsbol, T. O. (2018). Withaferin A and sulforaphane regulate breast cancer cell cycle progression through epigenetic mechanisms. Experimental Cell Research, 368(1), 67–74. https://doi.org/10.1016/j.yexcr.2018.04.015
  35. Royston, K., Udayakumar, N., Lewis, K., & Tollefsbol, T. (2017). A Novel Combination of Withaferin A and Sulforaphane Inhibits Epigenetic Machinery, Cellular Viability and Induces Apoptosis of Breast Cancer Cells. International Journal of Molecular Sciences, 18(5), 1092. https://doi.org/10.3390/ijms18051092
  36. Saeg, F., & Anbalagan, M. (2018). Breast cancer stem cells and the challenges of eradication: a review of novel therapies. Stem Cell Investigation, 5, 39–39. https://doi.org/10.21037/sci.2018.10.05
  37. Sever, R., & Brugge, J. S. (2015). Signal Transduction in Cancer. Cold Spring Harbor Perspectives in Medicine, 5(4), a006098–a006098. https://doi.org/10.1101/cshperspect.a006098
  38. Sun, Y.-S., Zhao, Z., Yang, Z.-N., Xu, F., Lu, H.-J., Zhu, Z.-Y., Shi, W., Jiang, J., Yao, P.-P., & Zhu, H.-P. (2017). Risk Factors and Preventions of Breast Cancer. International Journal of Biological Sciences, 13(11), 1387–1397. https://doi.org/10.7150/ijbs.21635
  39. Sundararajan, R. (2014). Electroporation-Based Therapies for Cancer. Elsevier. https://doi.org/10.1016/C2013-0-18150-0
  40. Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249.
  41. Vanduchova, A., Anzenbacher, P., & Anzenbacherova, E. (2019). Isothiocyanate from Broccoli, Sulforaphane, and Its Properties. Journal of Medicinal Food, 22(2), 121–126. https://doi.org/10.1089/jmf.2018.0024
  42. Wati, E. M., Puspaningtyas, A. R., & Pangaribowo, D. A. (2016). Uji Sitotoksisitas dan Proliferasi Senyawa 1- ( 4-nitrobenzoiloksi- metil ) -5-fluorourasil terhadap Sel Kanker Payudara MCF-7 methyl ) -5-fluorouracil ) on Breast Cancer Cells MCF-7 ). 4(3), 484–488.
  43. Windarti NI. (2022). Gambaran Subtipe Molekuler Kanker Payudara di Indonesia. Agromedicine, 9(5), 145–148.
  44. Wu, S., Lu, H., & Bai, Y. (2019). Nrf2 in cancers: A double‐edged sword. Cancer Medicine, 8(5), 2252–2267. https://doi.org/10.1002/cam4.2101
  45. Yersal, O. (2014). Biological subtypes of breast cancer: Prognostic and therapeutic implications. World Journal of Clinical Oncology, 5(3), 412. https://doi.org/10.5306/wjco.v5.i3.412
  46. Zhang, H., Zhang, Z., Du, G., Sun, H., Liu, H., Zhou, Z., Gou, X., Wu, X., Yu, X., & Huang, Y. (2019). Nrf2 promotes breast cancer cell migration via up‐regulation of G6PD/HIF‐1α/Notch1 axis. Journal of Cellular and Molecular Medicine, 23(5), 3451–3463. https://doi.org/10.1111/jcmm.14241
  47. Zimta, A.-A., Cenariu, D., Irimie, A., Magdo, L., Nabavi, S. M., Atanasov, A. G., & Berindan-Neagoe, I. (2019). The Role of Nrf2 Activity in Cancer Development and Progression. Cancers, 11(11), 1755. https://doi.org/10.3390/cancers11111755